Paricalcitol
Paricalcitol structure
|
Common Name | Paricalcitol | ||
|---|---|---|---|---|
| CAS Number | 131918-61-1 | Molecular Weight | 416.637 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 564.8±50.0 °C at 760 mmHg | |
| Molecular Formula | C27H44O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 238.3±24.7 °C | |
| Symbol |
GHS06, GHS08 |
Signal Word | Danger | |
|
Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.
Reprod. Sci. 21(9) , 1108-19, (2014) We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. W... |
|
|
Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney.
Am. J. Physiol. Renal Physiol. 307(12) , F1412-26, (2014) Mesenchymal stem cells (MSCs) suppress T helper (Th)17 cell differentiation and are being clinically pursued for conditions associated with aberrant Th17 responses. Whether such immunomodulatory effects are enhanced by coadministration of MSCs with other agen... |
|
|
Spotlight on paricalcitol in secondary hyperparathyroidism.
Treat. Endocrinol. 4(3) , 185-6, (2005) Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatme... |
|
|
Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model.
Eur. Rev. Med. Pharmacol. Sci. 18(19) , 2895-902, (2014) The effect of vitamin D and renin-angiotensin-aldosterone system blockade medications in pathophysiology of contrast induced nephropathy (CIN) is controversial. The effects of paricalcitol (active vitamin D analogue) and losartan treatments in an experimental... |
|
|
Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity.
Am. J. Physiol. Renal Physiol. 305(8) , F1109-17, (2013) 1, 25-Dihydroxycholechalciferol (calcitriol) and 19-nor-1, 25-dihydroxyvitamin D2 (paricalcitol) are vitamin D receptor (VDR) agonists. Previous data suggest VDR agonists may actually increase renin-angiotensin activity, and this has always been assumed to be... |
|
|
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Clin. J. Am. Soc. Nephrol. 10(1) , 98-109, (2015) Elevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction of practice guidelines suggesting higher parathyroid hormone targets than those previously recommended, changes in parathyroid... |
|
|
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Clin. Drug Investig. 26(11) , 629-38, (2006) This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary hyperparathyroidism, focusing on a third-party payer perspect... |
|
|
Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
Eur. J. Pharmacol. 709(1-3) , 72-9, (2013) Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease and frequently persists after kidney transplantation. Paricalcitol, a selective vitamin D receptor activator, is indicated in the management of this disorder and re... |
|
|
Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.
Drugs 65(4) , 559-76, (2005) Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and tre... |
|
|
Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model.
Isr. Med. Assoc. J. 15(11) , 693-7, (2013) Vitamin D has been shown to induce beneficial effects on cardiovascular and renal morbidity by regulating inflammation and tissue fibrosis.To evaluate the effect of vitamin D analogues on cardiac function and fibrosis in an animal model of cardiorenal syndrom... |